Eroqueen (chloroquine phosphate): Uses, Dosage & Side Effects

What it's for (Indications)

Chloroquine phosphate is a 4-aminoquinoline compound primarily indicated for the treatment and prophylaxis of malaria caused by susceptible strains of Plasmodium vivax, P.
malariae, P.
ovale, and uncomplicated P.
falciparum.
It is crucial to note that chloroquine is not effective against chloroquine-resistant strains of P.
falciparum or P.
vivax.
Therefore, its use for malaria must be guided by current epidemiological data regarding drug resistance patterns in the specific geographical area.
Additionally, chloroquine phosphate is indicated for the treatment of extraintestinal amebiasis, a parasitic infection caused by Entamoeba histolytica that has spread beyond the intestines.
This includes cases where amebic cysts or trophozoites are found in organs like the liver.
Its efficacy in these conditions relies on careful diagnosis and appropriate patient selection.

Dosage Information

Type	Guideline
Standard	The dosage of chloroquine phosphate varies significantly depending on the indication (treatment vs. prophylaxis), patient age, weight, and clinical status, requiring precise calculation and administration under medical supervision. For the treatment of uncomplicated malaria, adults typically receive an initial loading dose, followed by subsequent doses over 2-3 days. Pediatric dosing is strictly weight-based. For malaria prophylaxis, the adult dose is generally administered once weekly, commencing prior to exposure, throughout the stay in endemic areas, and for several weeks after departure. For extraintestinal amebiasis, a specific dosage regimen over several weeks is prescribed. Due to its narrow therapeutic index and potential for toxicity, particularly in overdose, strict adherence to the prescribed regimen is paramount. Any deviation, self-medication, or discontinuation without consulting a healthcare professional can lead to suboptimal outcomes or severe adverse events.

Type

Guideline

Standard

The dosage of chloroquine phosphate varies significantly depending on the indication (treatment vs. prophylaxis), patient age, weight, and clinical status, requiring precise calculation and administration under medical supervision. For the treatment of uncomplicated malaria, adults typically receive an initial loading dose, followed by subsequent doses over 2-3 days. Pediatric dosing is strictly weight-based. For malaria prophylaxis, the adult dose is generally administered once weekly, commencing prior to exposure, throughout the stay in endemic areas, and for several weeks after departure. For extraintestinal amebiasis, a specific dosage regimen over several weeks is prescribed. Due to its narrow therapeutic index and potential for toxicity, particularly in overdose, strict adherence to the prescribed regimen is paramount. Any deviation, self-medication, or discontinuation without consulting a healthcare professional can lead to suboptimal outcomes or severe adverse events.

Safety & Warnings

Common Side Effects

Chloroquine phosphate can induce a range of side effects, from mild and transient to severe and potentially life-threatening.
Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal cramps, which can often be mitigated by taking the medication with food.
Other frequently reported effects include headache, dizziness, and pruritus, particularly in individuals of African descent.
More serious, albeit less common, side effects include ocular toxicity (retinopathy, corneal deposits, irreversible vision loss, especially with long-term or high-dose use), cardiovascular effects (cardiomyopathy, QT prolongation, arrhythmias, hypotension), neurological disturbances (seizures, psychosis, peripheral neuropathy), and dermatological reactions (rash, hair loss, skin pigmentation changes, exacerbation of psoriasis).
Hematologic effects, such as bone marrow suppression or hemolytic anemia in G6PD-deficient individuals, can also occur.
Patients should be advised to report any new or worsening symptoms promptly.

Serious Warnings

Black Box Warning: While chloroquine phosphate does not carry a formal FDA Black Box Warning, it is associated with several critical and potentially fatal serious warnings that necessitate extreme caution. These include a high risk of overdose, especially in children, which can be fatal even at relatively low doses. Chloroquine is highly toxic in overdose, leading to rapid onset of cardiotoxicity (e.g., severe hypotension, arrhythmias, cardiac arrest), respiratory depression, seizures, and coma. There is also a significant risk of irreversible retinal damage (retinopathy) with prolonged or high-dose use, potentially leading to permanent blindness. Severe cardiac effects, including cardiomyopathy and QT prolongation leading to life-threatening arrhythmias, have been reported. Healthcare providers must ensure patients are fully aware of these severe risks, particularly regarding accidental overdose in children, and should provide explicit instructions for safe storage and administration. Close monitoring and careful patient selection are essential to mitigate these serious safety concerns.
Several critical warnings are associated with chloroquine phosphate use.
Of primary concern is the potential for irreversible retinal damage (retinopathy), which can lead to permanent vision loss.
This risk is heightened with prolonged use, high cumulative doses, and in patients with pre-existing ocular conditions.
Regular ophthalmologic examinations, including visual field testing and spectral-domain optical coherence tomography (SD-OCT), are imperative for patients on long-term therapy.
Cardiotoxicity, including cardiomyopathy, QT prolongation, and fatal arrhythmias, has been reported, necessitating caution in patients with pre-existing cardiac disease or those concurrently using other QT-prolonging drugs.
Chloroquine can also induce severe hypoglycemia, sometimes without warning, including in patients not on antidiabetic medications.
Neuropsychiatric effects, such as seizures and suicidal behavior, mandate careful monitoring, especially in individuals with a history of such conditions.
The drug may also exacerbate psoriasis, porphyria, and myasthenia gravis, and careful consideration is required in patients with G6PD deficiency due to the risk of hemolytic anemia.

How it Works (Mechanism of Action)

Chloroquine phosphate exerts its primary therapeutic effects through multiple mechanisms. As an antimalarial, it is a weak base that readily crosses parasitic and host cell membranes, accumulating significantly in the acidic food vacuole of the malaria parasite. Within this vacuole, chloroquine interferes with the parasite's detoxification of heme, a toxic byproduct of hemoglobin digestion. By inhibiting the heme polymerase enzyme, chloroquine prevents the polymerization of heme into non-toxic hemozoin. This leads to the accumulation of free heme, which is highly toxic to the parasite, causing oxidative stress and lysosomal membrane damage, ultimately leading to parasite death. Beyond its antimalarial action, chloroquine also possesses anti-inflammatory and immunomodulatory properties, though these are less central to its approved indications. These effects are thought to involve the stabilization of lysosomal membranes, inhibition of prostaglandin production, and modulation of antigen processing and presentation in immune cells.